A report released today by Wedbush about Alexion Pharma (NASDAQ:ALXN) raises the target price to $132.00
- Updated: September 23, 2016
Yesterday Alexion Pharma (NASDAQ:ALXN) traded -4.84% lower at $133.69. The company’s 50-day moving average is $130.81 and its 200-day moving average is $135.64. The last closing price is down -6.21% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 2,154,637 shares of the stock were exchanged, up from an average trading volume of 1,722,460
Alexion Pharma (NASDAQ:ALXN) had its target price raised to $132.00 by Wedbush in a report released Friday September 23, 2016. The new target price indicates a possible downside of -0.01% based on the company's last closing price.
Previously on 09/22/2016, Wedbush reported on Alexion Pharma (NASDAQ:ALXN) raised the target price from $0.00 to $132.00. At the time, this indicated a possible downside of -0.01%.
See Chart Below
Alexion Pharma has a PE ratio of 319.65 with a one year low of $110.56 and a one year high of $193.45 Alexion Pharma’s market capitalization is presently $0.
In addition to Wedbush reporting its stock price target, a total of 18 brokerages have issued a research note on the company. The average stock price target is $187.61 with seven analysts rating the company a strong buy, six analysts rating the company a buy, seven analysts rating the company a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Alexion Pharma (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.